---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Special populations"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Special populations. Topics: Performance status and cystectomy eligibility in the pivotal trial population, Older participants in BOND-003 Cohort C, Precautions for household contacts and sexual activity after each instillation, and Biosafety handling in the clinic. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/special-populations"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Performance status and cystectomy eligibility in the pivotal trial population

> “Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-2.1.2.8-2"></a>

### Older participants in BOND-003 Cohort C

> “median age was 74·0 years (IQR 68·5-79·5)”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.1.2.8-3"></a>

### Precautions for household contacts and sexual activity after each instillation

> “For 7 days after every treatment, patients should follow these precautions:”
> “Minimize/avoid direct contact with urine”
> “Highly effective birth control and barrier methods must be used during sexual activity”
> “Close contact (kissing, hugging) is fine if symptom-free”
> “Avoid contact with others up to 2 weeks if febrile illness, respiratory symptoms, or diarrhea are present”

Source: [Cohen (2026)](https://cgoncology.com/wp-content/uploads/2026/10/SUNA_2026_Cretostimogene_Optimized_Administration_Podium.pdf)

<a id="topic-2.1.2.8-4"></a>

### Biosafety handling in the clinic

> “Follow universal biosafety protocols- cretostimogene is BSL-2 like BCG”
> “Use appropriate protective equipment (e.g., gloves, gown, eye protection) during preparation and administration”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.1.2.8-5"></a>

### Use in pregnancy and lactation, in children, and in renal or hepatic impairment

No evidence found.

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
